Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Treasury Shares (2016 - 2025)

Editas Medicine (EDIT) has disclosed Treasury Shares for 11 consecutive years, with $652267.0 as the latest value for Q3 2025.

  • Quarterly Treasury Shares fell 74.32% to $652267.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $652267.0 through Sep 2025, down 74.32% year-over-year, with the annual reading at $2.3 million for FY2024, 10.41% up from the prior year.
  • Treasury Shares for Q3 2025 was $652267.0 at Editas Medicine, down from $923539.0 in the prior quarter.
  • The five-year high for Treasury Shares was $2.7 million in Q1 2024, with the low at $628732.0 in Q4 2021.
  • Average Treasury Shares over 5 years is $1.6 million, with a median of $1.5 million recorded in 2025.
  • The sharpest move saw Treasury Shares soared 138.43% in 2022, then tumbled 74.32% in 2025.
  • Over 5 years, Treasury Shares stood at $628732.0 in 2021, then skyrocketed by 138.43% to $1.5 million in 2022, then surged by 40.56% to $2.1 million in 2023, then grew by 10.41% to $2.3 million in 2024, then crashed by 71.96% to $652267.0 in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $652267.0, $923539.0, and $1.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.